Stimusil key facts
as of Oct 2026- Operator of a medical device company intended to develop proprietary methods for subdermal photobiomodulation.
- Stimusil is valued at approximately $29.2M as of Oct 2026 (last reported valuation).
- It has raised $10.3M across 3 recorded rounds; the latest was Seed Round ($600K) in Dec 2024.
- Notable investors include Toubkal Partners, Gen Ilac Ve Saglik, Northwestern University.
- Stimusil has filed 5 Form Ds with the SEC since 2022, most recently Mar 2025 ($600K sold to 2 investors).
- Status: Privately Held (backing).
Stimusil's last reported valuation, Aug 2023. Nothing priced has surfaced since.
- ·Watch Stimusil: the Monday email on marks, rounds and moves
Stimusil funding rounds
3 roundsWho backs Stimusil
3Stimusil valuation
Stimusil's last reported valuation was $29.2 million in Aug 2023. No priced round, secondary trade or fund mark has surfaced since.
How much has Stimusil raised?
Stimusil has raised $10.3 million in total; 3 of its rounds are on record, from 2022 on. The largest on record was a $599,988 seed round in Dec 2024.
Stimusil has filed 5 Form Ds with the SEC since 2022, most recently in Mar 2025 ($599,988 sold to 2 investors).
Stimusil investors
3 investors are on record for Stimusil, including Toubkal Partners, Gen Ilac Ve Saglik and Northwestern University. The seed round in Dec 2024 drew 2 investors.
About Stimusil
Operator of a medical device company intended to develop proprietary methods for subdermal photobiomodulation. The company's devices are used to deliver stimulation subdermally, using patented technology to cross the melanin layer, enabling medical professionals to have safe and effective photobiomodulation therapy.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2021
- Employees
- 10
- Website
- stimusil.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.